BCYC
Income statement / Annual
Last year (2024), Bicycle Therapeutics plc's total revenue was $35.28 M,
an increase of 30.76% from the previous year.
In 2024, Bicycle Therapeutics plc's net income was -$169.03 M.
See Bicycle Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$35.28 M |
$26.98 M |
$14.46 M |
$11.70 M |
$10.39 M |
$13.80 M |
$7.14 M |
$2.06 M |
$0.00 |
| Cost of Revenue |
$172.97 M
|
$156.50 M
|
$0.00
|
$0.00
|
$33.15 M
|
$25.54 M
|
$20.76 M
|
$11.87 M
|
$269.29 K
|
| Gross Profit |
-$137.69 M
|
-$129.52 M
|
$14.46 M
|
$11.70 M
|
-$22.76 M
|
-$11.74 M
|
-$13.63 M
|
-$9.81 M
|
-$269.29 K
|
| Gross Profit Ratio |
-3.9
|
-4.8
|
1
|
1
|
-2.19
|
-0.85
|
-1.91
|
-4.76
|
0
|
| Research and Development Expenses |
$172.97 M
|
$156.50 M
|
$81.61 M
|
$44.88 M
|
$33.15 M
|
$31.64 M
|
$20.76 M
|
$11.87 M
|
$9.77 M
|
| General & Administrative Expenses |
$71.46 M
|
$59.83 M
|
$49.51 M
|
$32.44 M
|
$29.20 M
|
$14.56 M
|
$8.12 M
|
$6.41 M
|
$3.78 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$325.11 K
|
| Selling, General & Administrative Expenses |
$71.46 M
|
$59.83 M
|
$49.51 M
|
$32.44 M
|
$29.20 M
|
$14.56 M
|
$8.12 M
|
$6.41 M
|
$3.45 M
|
| Other Expenses |
-$172.25 M
|
-$155.90 M
|
$0.00
|
$0.00
|
-$33.15 M
|
-$31.64 M
|
-$665.00 K
|
-$119.00 K
|
$0.00
|
| Operating Expenses |
$72.18 M
|
$60.43 M
|
$131.12 M
|
$77.32 M
|
$29.20 M
|
$14.56 M
|
$28.88 M
|
$18.27 M
|
$13.22 M
|
| Cost And Expenses |
$245.15 M
|
$216.92 M
|
$131.12 M
|
$77.32 M
|
$62.35 M
|
$40.10 M
|
$28.88 M
|
$18.27 M
|
$13.49 M
|
| Interest Income |
$34.28 M
|
$14.00 M
|
$5.76 M
|
$120.00 K
|
$683.00 K
|
$814.00 K
|
$169.00 K
|
$50.00 K
|
$8.00 K
|
| Interest Expense |
$1.73 M
|
$3.26 M
|
$3.34 M
|
$2.98 M
|
$457.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$7.18 M
|
$6.55 M
|
$3.69 M
|
$1.41 M
|
$1.28 M
|
$960.00 K
|
$710.80 K
|
$335.56 K
|
$269.29 K
|
| EBITDA |
-$164.89 M |
-$183.40 M |
-$107.21 M |
-$64.09 M |
-$50.68 M |
-$25.34 M |
-$21.49 M |
-$15.88 M |
-$13.26 M |
| EBITDA Ratio |
-4.67
|
-6.8
|
-7.41
|
-5.48
|
-4.88
|
-1.84
|
-3.01
|
-7.71
|
0
|
| Operating Income Ratio |
-5.95
|
-7.04
|
-8.07
|
-5.61
|
-5
|
-1.91
|
-3.05
|
-7.87
|
0
|
| Total Other Income/Expenses Net |
$36.08 M
|
$10.74 M
|
$2.41 M
|
-$2.86 M
|
$226.00 K
|
-$4.56 M
|
-$496.00 K
|
-$69.00 K
|
-$37.90 K
|
| Income Before Tax |
-$173.80 M
|
-$179.21 M
|
-$114.24 M
|
-$68.48 M
|
-$51.73 M
|
-$30.86 M
|
-$22.24 M
|
-$16.28 M
|
-$13.53 M
|
| Income Before Tax Ratio |
-4.93
|
-6.64
|
-7.9
|
-5.85
|
-4.98
|
-2.24
|
-3.12
|
-7.9
|
0
|
| Income Tax Expense |
-$4.77 M
|
$1.46 M
|
-$1.52 M
|
-$1.66 M
|
-$724.00 K
|
-$254.00 K
|
-$396.00 K
|
-$23.00 K
|
-$20.94 K
|
| Net Income |
-$169.03 M
|
-$180.66 M
|
-$112.72 M
|
-$66.82 M
|
-$51.01 M
|
-$30.61 M
|
-$21.85 M
|
-$16.26 M
|
-$13.51 M
|
| Net Income Ratio |
-4.79
|
-6.7
|
-7.79
|
-5.71
|
-4.91
|
-2.22
|
-3.06
|
-7.89
|
0
|
| EPS |
-2.91 |
-5.08 |
-3.8 |
-2.67 |
-2.66 |
-2.77 |
-1.64 |
-1.22 |
-0.76 |
| EPS Diluted |
-2.9 |
-5.08 |
-3.8 |
-2.67 |
-2.66 |
-2.77 |
-1.64 |
-1.22 |
-0.76 |
| Weighted Average Shares Out |
$58.21 M
|
$35.59 M
|
$29.66 M
|
$25.06 M
|
$19.15 M
|
$11.05 M
|
$13.29 M
|
$13.29 M
|
$17.70 M
|
| Weighted Average Shares Out Diluted |
$58.21 M
|
$35.59 M
|
$29.66 M
|
$25.06 M
|
$19.15 M
|
$11.05 M
|
$13.29 M
|
$13.29 M
|
$17.70 M
|
| Link |
|
|
|
|
|
|
|
|
|
